• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: AIZU OLYMPUS CO., LTD. EVIS LUCERA GASTROINTESTINAL VIDEOSCOPE

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

AIZU OLYMPUS CO., LTD. EVIS LUCERA GASTROINTESTINAL VIDEOSCOPE Back to Search Results
Model Number GIF-H260
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problems Hemorrhage/Bleeding (1888); Perforation (2001)
Event Date 09/22/2022
Event Type  Injury  
Event Description
Olympus reviewed the following literature titled "long-term outcome of the endoscopic submucosal dissection of early gastric cancer: a comparison between patients with and without liver cirrhosis." abstract: gastric cancer (gc) and liver cirrhosis (lc) have high incidence rates, particularly in eastern asia; however, the long-term clinical outcomes or recurrence of gc following endoscopic submucosal dissection (esd) in patients with comorbid lc remain unclear.The present study aimed to compare the long-term efficacy and safety of esd in patients with gc, with and without lc.Patients with early gc (egc) who had underlying lc and underwent endoscopic treatment (lc-egc group) were enrolled in the present study.In addition, patients with egc without lc (non-lc-egc group) were matched at a ratio of 1:3 via propensity score matching.The clinical outcomes and histopathological data of both groups were analyzed.No significant differences were observed in procedure type, complications [intraprocedural bleeding (11.8%) and perforation (0.0%)], en bloc resection rate (94.1%) and complete resection rate (100%) between the two groups.Multivariate cox regression analysis demonstrated that procedure time was significantly associated with procedure-associated bleeding [adjusted hazard ratio (hr), 1.017; 95% confidence interval (ci), 1.001-1.032; p=0.033].Furthermore, lc was significantly associated with cancer recurrence (adjusted hr, 5.482; 95% ci, 1.102-27.279; p=0.038).Taken together, the results of the present study suggest that endoscopic resection of egc in patients with lc is an effective and safe treatment method.However, further studies are required to assess recurrence.Type of adverse events/number of patients: bleeding - 13, perforation - 2, death -1, recurrence -7, this literature article requires 2 reports.The related patient identifiers are as follows: (b)(6) :kd-610l, (b)(6) :gif-h260.This medwatch report is for patient identifier: (b)(6).The death was determined to be not reportable.There is no report of any olympus device malfunction in any procedure described in this study.
 
Manufacturer Narrative
The suspect device has not been returned to olympus for evaluation.The investigation is in process.The literature article is attached for additional information.Once the investigation has been completed, a supplemental report will be submitted with device evaluation results.
 
Event Description
The following additional information was received from the author: it was confirmed that an olympus device did not cause or contribute to any of the adverse events described in the article.In addition, an olympus device did not malfunction in any of the procedures described in the article.
 
Manufacturer Narrative
This report is being supplemented to provide additional information based on the legal manufacturer's final investigation.The device history record was unable to be reviewed for this device since the serial and/or lot number was not provided.However, olympus only releases products to market that meet all manufacturing specifications and final product release criteria.Based on the results of the investigation, the relationship between the device and the adverse event cannot be confirmed.There was no complaint reported on the subject device.There is no evidence of an olympus device malfunction.Therefore, the root cause cannot be determined.This supplemental report includes a correction to d8 to provide information that was not included on the initial medwatch.In addition, new information was received from the author and added to b5.Olympus will continue to monitor field performance for this device.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
EVIS LUCERA GASTROINTESTINAL VIDEOSCOPE
Type of Device
GASTROINTESTINAL VIDEOSCOPE
Manufacturer (Section D)
AIZU OLYMPUS CO., LTD.
3-1-1 niiderakita
aizuwakamatsu-shi, fukushima 965-8 520
JA  965-8520
Manufacturer (Section G)
AIZU OLYMPUS CO., LTD.
3-1-1 niiderakita
aizuwakamatsu-shi, fukushima
Manufacturer Contact
todd brill
800 west park drive
westborough, MA 01581
5082077661
MDR Report Key16163248
MDR Text Key307518840
Report Number9610595-2023-00775
Device Sequence Number1
Product Code FDS
Combination Product (y/n)N
Reporter Country CodeKS
PMA/PMN Number
K011151
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Other,Foreign,Study,Literature,Health Professional,Company Representative
Reporter Occupation Physician
Type of Report Initial,Followup
Report Date 04/04/2023
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Model NumberGIF-H260
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Was the Report Sent to FDA? No
Initial Date Manufacturer Received 12/18/2022
Initial Date FDA Received01/13/2023
Supplement Dates Manufacturer Received01/19/2023
Supplement Dates FDA Received04/04/2023
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Is the Device Single Use? No
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Reuse
Patient Sequence Number1
Patient Outcome(s) Required Intervention; Other;
-
-